- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
BCR Inhibitors Show Promise in Treating Chronic Lymphocytic Leukemia
March 25, 2013
Article
Two novel, oral drugs that target the B-Cell receptor signal transduction pathway could significantly change the way chronic lymphocytic leukemia is treated.
Dr. Jennifer Brown on Gauging Response in CLL
February 20, 2013
Video
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses gauging response in chronic lymphocytic leukemia.
Dr. Sara Tolaney on Cabozantinib in Breast Cancer
January 16, 2013
Video
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.
Dr. Mayer on Tivozanib in Kidney and Breast Cancer
November 30, 2012
Video
Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.
Dr. Taplin on the Mechanism of Action of Enzalutamide
November 29, 2012
Video
Mary-Ellen Taplin, MD, from the Dana-Farber Cancer Institute, discusses unique mechanism of action of enzalutamide in metastatic castration-resistant prostate cancer.
Overcoming Genetic Transformation in Multiple Myeloma
November 06, 2012
Article
The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, which is best achieved by targeted combination therapy very early in the course of disease.
Dr. Demetri Describes the MOA of Regorafenib in GIST
September 10, 2012
Video
Dr. George Demetri, from the Dana-Farber Cancer Institute, Describes the Mechanism of Action of Regorafenib in Gastrointestinal Stromal Tumors.
Dr. Demetri Explains the Side Effects of Regorafenib
June 20, 2012
Video
Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.